LDS/Medical Tests/Prothrombin Time (PT) with INR

Prothrombin Time (PT) with INR

The Prothrombin Time (PT) is a test of the extrinsic and common coagulation pathways. The PT is used as a general screening test (along with the aPTT) in the evaluation of bleeding, and to monitor oral anticoagulant therapy (warfarin/Coumadin). Oral warfarin inhibits the synthesis of vitamin K dependent coagulation factors, thus decreasing the clotting tendency in patients that exhibit inappropriate coagulation. The PT is sensitive to decreased levels of factors II, V, VII, X, and fibrinogen.  It is not influenced by levels of factors VIII, IX, XI, XII or XIII.  Just as the PT is sensitive to vitamin K deficiency it is also sensitive to a vitamin K increase. When dietary vitamin K changes, altering the intake of vitamin K, oral warfarin must also be altered. This is another reason for the monitoring of Coumadin therapy with the PT.

Liver damage such as alcoholic cirrhosis, hepatitis, or hepatocellular carcinoma can also prolong the PT because of the decreased production of the coagulation factors associated with the PT.   The PT can be influenced slightly (usually < 1 second) by heparin. The PT is always reported together with the prothrombin ratio (International Normalized Ratio or INR). Because reagents and testing platforms introduce a degree of variability to the raw prothrombin time result, the calculated INR was devised to standardize results regardless of the reagents and instrumentation used for testing. Because of this, some clinical laboratories only report the INR because it remains relatively stable from lab to lab, whereas the PT can fluctuate.

The INR, or International Normalized Ratio, is calculated from the result of the prothrombin time (PT). It is reported with every PT result. The calculation also uses a number called the mean of normal patients. The mean of normal patients is established by averaging a statistically significant number of normal PT results. The formula for INR is: INR = (PT test/PT normal) raised to the power of ISI. The patient’s PT result is divided by the geometric mean of the PT of the normal population. This ratio is then taken to the power of the ISI (international sensitivity index). The ISI is the third component needed to calculate an INR value. The ISI is a factor based on the sensitivity of the PT reagent being used and is provided by the instrument and reagent manufacturer of the equipment used to test the PT.

The PT-INR is used to evaluate for coagulation defects, assess DIC, evaluate liver function, help evaluate for vitamin K deficiency and monitor patients taking oral anticoagulant therapy with warfarin (Coumadin). These drugs help to inhibit the formation of blood clots. Coumadin is used in patients with a history of inappropriate clot formation, heart attack, stroke, deep vein thrombosis (DVT), and artificial heart valves. It is also given to patients on a short-term basis for other surgeries. For further information see also Prothrombin time (PT).

  • Diagnosis of clotting disorders
  • Evaluation of blood clotting as a screening test for certain factor deficiencies (I, II, V, VII, X) due to either hereditary or acquired diseases.
  • As a screening test for coagulation inhibitors (e.g., specific factor inhibitors, antiphospholipid syndrome, elevated immunoglobulins)
  • Aids evaluation for DIC as part of a multi-test screening panel
  • Monitoring of oral anticoagulant therapy (warfarin/Coumadin) using the INR.

Increased in:

  • Warfarin and other anti-clotting therapy
  • Liver disease
  • Disseminated intravascular coagulation (DIC)
  • Vitamin K deficiency
  • Hereditary deficiency in factors VII, X, V, and II
  • Fibrinogen abnormality (e.g., hypofibrinogenemia, afibrinogenemia, dysfibrinogenemia)
  • Circulating anticoagulant affecting the PT system, such as in antiphospholipid antibodies
  • Massive transfusion

In general: 11-15 sec
Monitoring warfarin: INR generally: 2.0-3.0

INR: International Normalized Ratio

Clot detection.

Plasma Citrate (Light Blue). 

Freeze immediately and maintain frozen until tested.

Stability

  • Ambient: Unacceptable
  • Refrigerated: Unacceptable
  • Frozen: 14 days
aPTT, Fibrinogen, Mixing Studies (with reflex to specific factor levels or factor inhibitor assay if indicated), International Normalized Ratio, Warfarin Assay by Pharmacogenomics (CYP2C9 and VKORC1 gene variation), Platelet count.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Thromb Haemost. 2002;87:74. [PMID: 11848460]
  • J Thromb Haemost.2006;4:967. [PMID: 16689743]
  • Kottke-Merchan K. An Algorithmic Approach to Hemostasis Testing. Northfield: College of American Pathologists (CAP) Press (2008).